Literature DB >> 24019329

Epigenetic approaches for chemosensitization of refractory diffuse large B-cell lymphomas.

James J Steinhardt1, Ronald B Gartenhaus.   

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma, with the greatest challenge for improving patient survival being the management of chemorefractory disease upon relapse. Epigenetic dysregulation has been correlated with more-aggressive malignancies and chemoresistance. In this issue of Cancer Discovery, Clozel and colleagues show the potential for low-dose DNA methyltransferase inhibitors as both a rational and an effective neoadjuvant approach for chemosensitization in DLBCL. ©2013 AACR.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24019329      PMCID： PMC3856881          DOI： 10.1158/2159-8290.CD-13-0358

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  14 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

2.  BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.

Authors:  Leandro C Cerchietti; Katerina Hatzi; Eloisi Caldas-Lopes; Shao Ning Yang; Maria E Figueroa; Ryan D Morin; Martin Hirst; Lourdes Mendez; Rita Shaknovich; Philip A Cole; Kapil Bhalla; Randy D Gascoyne; Marco Marra; Gabriela Chiosis; Ari Melnick
Journal:  J Clin Invest       Date:  2010-11-01       Impact factor: 14.808

3.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.

Authors:  Michael T McCabe; Heidi M Ott; Gopinath Ganji; Susan Korenchuk; Christine Thompson; Glenn S Van Aller; Yan Liu; Alan P Graves; Anthony Della Pietra; Elsie Diaz; Louis V LaFrance; Mark Mellinger; Celine Duquenne; Xinrong Tian; Ryan G Kruger; Charles F McHugh; Martin Brandt; William H Miller; Dashyant Dhanak; Sharad K Verma; Peter J Tummino; Caretha L Creasy
Journal:  Nature       Date:  2012-10-10       Impact factor: 49.962

4.  Activation of the p21(CIP1/WAF1) promoter by bone morphogenetic protein-2 in mouse B lineage cells.

Authors:  K Yamato; S Hashimoto; T Imamura; H Uchida; N Okahashi; T Koseki; A Ishisaki; M Kizaki; K Miyazono; Y Ikeda; T Nishihara
Journal:  Oncogene       Date:  2001-07-19       Impact factor: 9.867

5.  Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma.

Authors:  Fazila Asmar; Vasu Punj; Jesper Christensen; Marianne T Pedersen; Anja Pedersen; Anders B Nielsen; Christoffer Hother; Ulrik Ralfkiaer; Peter Brown; Elisabeth Ralfkiaer; Kristian Helin; Kirsten Grønbæk
Journal:  Haematologica       Date:  2013-07-05       Impact factor: 9.941

6.  DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation.

Authors:  Rita Shaknovich; Leandro Cerchietti; Lucas Tsikitas; Matthias Kormaksson; Subhajyoti De; Maria E Figueroa; Gianna Ballon; Shao Ning Yang; Nils Weinhold; Mark Reimers; Thomas Clozel; Karin Luttrop; Tomas J Ekstrom; Jared Frank; Aparna Vasanthakumar; Lucy A Godley; Franziska Michor; Olivier Elemento; Ari Melnick
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

Review 7.  Functions of DNA methylation and hydroxymethylation in mammalian development.

Authors:  Sylvain Guibert; Michael Weber
Journal:  Curr Top Dev Biol       Date:  2013       Impact factor: 4.897

8.  TGFbeta-mediated activation of Smad1 in B-cell non-Hodgkin's lymphoma and effect on cell proliferation.

Authors:  O Munoz; F Fend; R de Beaumont; H Husson; A Astier; A S Freedman
Journal:  Leukemia       Date:  2004-12       Impact factor: 11.528

9.  Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells.

Authors:  N Chapman-Rothe; E Curry; C Zeller; D Liber; E Stronach; H Gabra; S Ghaem-Maghami; R Brown
Journal:  Oncogene       Date:  2012-11-05       Impact factor: 9.867

10.  Loss of expression of HDAC-recruiting methyl-CpG-binding domain proteins in human cancer.

Authors:  C Müller-Tidow; K Kügler; S Diederichs; S Klümpen; M Möller; U Vogt; R Metzger; P M Schneider; W E Berdel; H Serve
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640
View more
  3 in total

1.  Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.

Authors:  Rohit Mathur; Lalit Sehgal; Ondrej Havranek; Stefan Köhrer; Tamer Khashab; Neeraj Jain; Jan A Burger; Sattva S Neelapu; R Eric Davis; Felipe Samaniego
Journal:  Haematologica       Date:  2016-10-14       Impact factor: 9.941

2.  Methylation of CHFR sensitizes esophageal squamous cell cancer to docetaxel and paclitaxel.

Authors:  Tianyang Yun; Yang Liu; Dan Gao; Enqiang Linghu; Malcolm V Brock; Dongtao Yin; Qimin Zhan; James G Herman; Mingzhou Guo
Journal:  Genes Cancer       Date:  2015-01

Review 3.  The RNA Methyltransferase NSUN2 and Its Potential Roles in Cancer.

Authors:  Anitha Chellamuthu; Steven G Gray
Journal:  Cells       Date:  2020-07-22       Impact factor: 6.600
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.